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ABSTRACT 
 
Transgenic animals are animals that are genetically altered to have traits that mimic symptoms of specific 
human  pathologies.  They  provide  genetic  models  of  various  human  diseases  which  are  important  in 
understanding disease and developing new targets. In early 1980 Gordon and co-workers described the first 
gene  addition  experiment using  the  microinjection  technology  and  since  then  the  impact  of  transgenic 
technology on basic research has been significant. Within 20 years of its inception, ATryn the first drug 
approved  by  USFDA  from  transgenic  animals  was  developed  and  it  has  opened  door  to  drugs  from 
transgenic animals. In addition, they are looked upon as potential future donors for xenotransplantation. 
With increasing knowledge about the genetics and improvements in the transgenetic technology numerous 
useful applications  like biologically safe  new-generation drugs based on human regulatory proteins are 
being developed.Various aspects of concern in the coming years are the regulatory guidelines, ethical issues 
and  patents  related  to  the  use  of  transgenic  animals.  This  modern  medicine  is  on  the  threshold  of  a 
pharmacological  revolution.  Use  of  transgenic  animals  will  provide  solutions  for  drug  research, 
xenotransplantation, clinical trials and will prove to be a new insight in drug development. 
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INTRODUCTION 
 
With the advent of transgenic technology and its 
application in many laboratories around the world, 
there is an increase in the generation and use of 
genetically  modified  animals  in  biomedical, 
pharmaceutical  research  and  safety  testing.  This 
development has been additionally accelerated by 
the decoding the genome of man, mouse and rat.
1 
Pharmaceutical  companies  are  faced  with  the 
challenge that about 10% of compounds tested in 
clinical trials make to the market and, out of these, 
a minority will generate significant profit. The cost 
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of identifying new drug is immense, about United 
States (US) $ 800 million and 80% of this cost is 
spent  in  clinical  trials  and  development. 
Transgenic  technology  has  potential  to  influence 
the  attrition  rate  in  pharmaceutical  research  by 
increasing  the  quality  of  both  targets  and 
compounds. 
2 
To  date  most  of  the  medicines  are  synthetically 
produced and will continue in future. However, the 
challenge  for  the  pharmaceutical  industry  is  the 
development of ‘Biotech medicines’ which include 
therapeutic  proteins  such  as  enzymes  and 
antibodies. 
3   The global market for recombinant 
proteins  from  domestic  animals  is  expected  to 
exceed US$1 billion in 2008 and reach US$18. 6 
billion in 2013.
4 The two major animal systems of 
production are pharmaceutical proteins in milk and 
egg white from transgenic animals. 
1 
Since the first transgenic mice were generated in 
1982,  transgenic  animal  models  have  been  used 
extensively  to  investigate  biomedical  important 
mechanisms  underlying  a  variety  of  diseases,  to 
develop  and  evaluate  new  therapies.
  5  Thus 
transgenic  animals  have  the  ability  to  fulfill  the 
needs  of  the  pharmaceutical  industry  and  in 
coming  years  they  are  looked  as  potential 
contributors to the drugs and research in medicine. 
 
Making of Transgenic Animals 
There are three types of laboratory animal models 
mentioned in the literature. They are spontaneous, 
induced and transgenic. Spontaneous models shape 
up  as  a  result  of  naturally  occurring  mutations. 
Induced  models  are  produced  by  a  laboratory 
procedure  like  administration  of  a  drug  or 
chemicals,  feeding  of  special  diets  or  surgical 
procedure. The third category includes transgenic 
models.
6Transgenic  refers  to  insertion  of  cDNA 
(complimentary deoxyribonucleic acid) made from 
specific mRNA (messenger ribonucleic acid) into 
cells.
7 A transgenic animal is defined as an animal 
which is altered by the introduction of recombinant 
DNA through human intervention. 
8   
Following  sequence  is  generally  adopted  for  the 
development of transgenic animals irrespective of 
species: 
1, 9 
  Identification  and  construction  of  the  foreign 
gene and any promoter sequences 
  Introduction  of  DNA  directly  into  the 
pronucleus of a single fertilized egg by various 
methods 
  Implantation  of  these  engineered  cells  into 
surrogate mothers 
  Bringing  the  developing  embryo  to  term, 
proving that the foreign DNA has been stably 
and heritably incorporated into the DNA of at 
least some of the newborn offspring. 
  Demonstrating that the gene is regulated well 
enough to function in its new environment.  
The  foreign  DNA  can  be  inserted  into  the 
pronucleus  or  cytoplasm  of  the  embryo  using 
microinjections  or  transposon.  Other  methods  of 
DNA transfer are by lentivirus, sperms, pluripotent 
cells  and  cloning.  The  last  three  methods  allow 
random gene addition and targeted gene integration 
via  homologous  recombination  or  gene 
replacement  thus  causing  mutation. 
1,6  Targeted 
mutation  refers  to  a  process  whereby  a  specific 
gene (removal of a gene or part of a gene) is made 
nonfunctional  (knocked-out)  or  less  frequently 
made  functional  (knocked-in). 
4,  7  A  transgenic 
organism  carrying  more  than  one  transgenes  is 
known as multiple transgenic. 
4These methods do 
not  create  new  species,  but  only  offer  tools  for 
producing new strains of animals that carry novel 
genetic information. 
10 
 
Transgenic Animal models of various diseases 
An animal model is  a living, non-human  animal 
used  for  research  and  investigation  of  human 
disease, for the purpose of better understanding the 
disease without the added risk of causing harm to a 
human being during the entire drug discovery and 
development  process.  Transgenic  animal  models 
are created by the insertion of a particular human 
DNA  into  fertilized  oocytes  which  are  then 
allowed to develop to term by implantation into the 
oviducts  of  pseudo  pregnant  females.
6 There  are 
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different models of transgenic animals for various 
diseases. 
 
A.  Human Immunodeficiency Virus/ Acquired 
Immunodeficiency Syndrome (HIV/AIDS): 
Tg26  HIVAN  Mouse  Model  was  the  first 
transgenic  model  developed  in  1991  for  HIV. 
Since  than  many  models  have  developed, 
Rosenstiel  et  al  gives  summary  of  32  transgenic 
murine  HIVAN  models  developed. 
11  These 
transgenic  animals  can  express  HIV-1  proteins; 
develop  symptoms  and  immune  deficiencies 
similar to the manifestations of AIDS in humans. 
12 
Other models are AIDS Mouse and Smart Mouse. 
6 
B.  Alzheimer’s  disease:  No  animal  models 
existed  for  the  disease  before  transgenic 
technology  was  employed.  Immunization  of 
Amyloid precursor protein A42 in transgenic mice 
showed  that  vaccination  against  Alzheimer’s 
disease  could  have  potential  as  a  therapeutic 
approach.
2,  6  Different  animal  models  like 
Alzheimer’s  mouse,  amyloid  pathology  mouse 
models like PDAPP mice, Tg2576 mice, 
13, 14 TAU 
transgenic mouse models like ALZ7 mice, 7TauTg 
mice and presenilin transgenic models like ApoE 
knockout  are  developed  to  study  Alzheimer’s 
disease.
 13, 15 
C.  Cardiovascular disease: Various transgenic 
animal models for gain and or loss of function of 
angiotensin,  endothelin,  natriuretic  peptides, 
catechoalmines,  Calcium  binding-signaling, 
sodium  channel  transporters,  and  nitric  oxide 
synthesis involved in cardiovascular regulation are 
used to study cardiovascular diseases.
16  Transgenic 
models of heart failure and hypertrophy like Gene 
overexpression of  Calmodulin, Gene mutation of 
alpha  cardiac myosin heavy  chain and  Knockout 
gene  model  of  transforming  growth  factor  are 
developed.
17  Mutation  of  the  ApoE  gene  that  is 
critical for uptake of chylomicrons and very low-
density lipoprotein particles, results in a model that 
develops  atherosclerotic  lesions  histologically 
similar to those found in humans.
2 
D.  Diabetes  Mellitus:  Transgenic  models  are 
developed for studying the genes, and their role in 
peripheral  insulin  action.  Models  of  insulin 
secretion  such  as  glucokinase,  islet  amyloid 
polypeptide,  and  hepatic  glucose  production  in 
type  2  diabetes  are  developed. 
18A  transgenic 
mouse  model  that  expressed  Insulin  Dependent 
Diabetes Mellitus by inserting a viral gene in the 
animal  egg  stage  is  also  developed.
19  There  are 
other models  like beta receptor knockout  mouse, 
uncoupling protein (UCP1) knockout mouse,acute 
and  chronic  models  for  the  evaluation  of 
antidiabetic agents.
 18, 20, 21, 22 
E.  Angiogenesis:  Mouse  models  of 
angiogenesis,  arterial  stenosis,  atherosclerosis, 
thrombosis,  thrombolysis  and  bleeding  addresses 
techniques  to  evaluate  vascular  development.
23 
Inhibition of angiogenesis is currently one of the 
biggest  opportunities  for  new  cancer  therapies. 
With  the  help of  angiogenesis  transgenic  animal 
models  inhibitors  are  identified  which  act  on 
specific mechanisms of angiogenesis. 
2   
F.  Cancer  diseases:  Oncomouse  was  first 
transgenic animal to be patented. Its germ cells and 
somatic cells contain an activated human oncogene 
sequence  introduced  into  the  animal  at  an  early 
embryonic  stage  to  ensure  that  the  oncogene  is 
present  in  all  the  animal  cells.
6  Mechanisms  for 
tumor progression and metastasis via E-cadherin, 
and  other  adhesion  molecules  is  possible  by 
various transgenic knockout models.
 7 
Transgenic  animal  models  are  used  in  the 
assessment  of  mutagenicity,  carcinogenicity  and 
tools  for  understanding  metabolic  enzymes  and 
receptors. 
24 There  are  transgenic  animal  models 
for  mutagenicity  assays  approved  by  the  World 
Health  organization  like  LACItransgenic  model 
(Big  Blue®  construct)  and  LACZ  transgenic  
model  (Muta™Mouse  construct). 
25Variety  of 
transgenic  animals  have  been  generated  by 
different strategies in experimental immunotherapy 
of cancer, each aims to activate different immune 
system components. Some of them are transgenic 
rodent  models  expressing  tumor  associated 
antigens  like  MUC1  transgenic  mice,  Oncogene 
transgenic  mice  to  study  immunotherapeutic 
strategies,  transgenic  mice  expressing  immune 
effector cell molecules like Fc-receptor transgenic 
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mice 
5  The preclinical transgenic model of Matrix 
Metalloproteinase  (MMP)  inhibitors  studies  the 
bioactive  products  of  MMP  and  their  possible 
effects on cell physiology. 
26  Animal  models for 
Huntington’s disease, skeletal muscle disease and 
other diseases are also developed.
27, 28 
Disease models are needed in medicine so that one 
can  discover  the  targets  for  drug  development. 
Adding  and  deleting  genes  in  these  animals 
provide them new properties that make them useful 
for  better  understanding  of  disease  or 
manufacturing a cure. It is not ethical or safe to 
perform the initial tests in humans, so transgenic 
animals are used. As the testing of new vaccines 
and  drugs  must  first  be  performed  on  animals, 
these disease models are indispensable. 
6 
 
Products from Transgenic Animals 
Most  transgenic  species  are  studied  for  research 
applications  as  well  as  potential  commercial 
pharmaceutical productively. Here are some of the 
transgenic  animals  and  their  products  in 
development. 
Goats: Monoclonal Antibodies (MAbs) , Ig fusion 
proteins,  tPA  (tissue  Plasminogen  Activator), 
ATryn (recombinant human antithrombin III) is the 
first  transgenic  recombinant  protein  from 
transgenic animal  approved by the United  States 
Food  and  Drug  Administration  (USFDA)  in 
January 2009. 
9,29 
Chickens  and  Eggs:  vaccines;  interferons, 
cytokines; Human Serum Albumin (HSA), insulin, 
MAbs. 
9 
Pigs:  organs  for  xenotransplantation,  human 
hemoglobin, human protein C. 
9,30,31 
Cows: Factors VIII and IX, protein C, recombinant 
antithrombin  III  (rATIII), recombinant HSA, and 
human milk protein. 
9 
Mice:  expression  of  malaria  protein  for  vaccine 
development; MAbs, ATIII, beta interferon; cystic 
fibrosis transmembrane regulator; Factor X, HSA, 
tPA,  myelin  basic  protein;  prolactin;  fibrinogen 
and antineoplastic urinary protein.
 9 
Rabbits: recombinant human C1 inhibitor, human 
erythropoietin,  human  alpha  antitrypsin,  human 
interleukin 2, tPA, alpha glucosidase, and human 
growth hormone. 
9 
Sheep:  sheep  milk  includes  fibrinogen  (major 
constituent, with thrombin and Factor XIII) human 
Factor  VII,  Factor  IX,  activated  protein  C  and 
alpha-1-antitrypsin.
 9,31 
Other  Species:  Frogs,  nematodes,  and  marine 
invertebrates  have  been  used  to  study  various 
promoter elements and gene transfer technology. 
9 
Currently  in  most  pharmaceutical  companies, 
relatively large numbers of targets are validated to 
varying  extents  and  progressed  to  the  high 
throughput  screening  stage.  The  drugs  acting  on 
these targets are then used in clinical trials where 
the  attrition  rate  is  generally  high,  this  makes  it 
extremely costly. It is believed that the greater use 
of  transgenic  models  could  reduce  the  required 
throughput  for  achieving  success  and  thereby 
significant impact on costs.
10 
 
Drugs  from  Transgenic  Animals  and  Other 
Applications: 
Proteins started being used as pharmaceuticals in 
the 1920s with insulin extracted from pig pancreas. 
In the early 1980s, human insulin was prepared in 
recombinant bacteria and is now used by most of 
the diabetic patients. This success was limited as 
bacteria cannot synthesize complex proteins such 
as  monoclonal  antibodies  or  coagulation  blood 
factors that must be matured by post-translational 
modifications to be active or stable in vivo. These 
can  be  fully  achieved  only  in  mammalian  cells 
which  can  be  cultured  in  fermenters  or  used  in 
living  animals.  Several  transgenic  animals  can 
produce  recombinant  proteins  but  presently  two 
systems  started  being  implemented.  The  first  is 
milk  of  transgenic  mammals  and  the  second 
system  are  chicken  egg  white.  A  variety  of 
recombinant  proteins  which  includes  antibodies, 
vaccines, blood factors, hormones, growth factors, 
cytokines,  enzymes,  milk  proteins,  collagen, 
fibrinogen  and  others  are  being  developed  in 
transgenic animals. 
1,3,31 
The  mammary  gland is  the  preferred production 
site, because of the quantities of protein that can 
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be produced in this organ and established methods 
for  extraction  and  purification  of  these 
proteins.Products  derived  from  the  mammary 
gland of transgenic goats and sheep are ATIII, α-
antitrypsin  and  tPA.  ATIII  is  employed  for  the 
treatment of heparin-resistant patients undergoing 
cardiopulmonary  bypass.  The  enzyme  α-
glucosidase from the milk of transgenic rabbits has 
been successfully used for Pompe’s disease. 
4, 31 
Blood, seminal plasma, urine, silk gland and insect 
larvae haemolymph are other theoretically possible 
systems. Blood most of the time cannot store high 
levels of recombinant proteins which are naturally 
unstable also biologically active proteins in blood 
may alter the health of the animals. Milk avoids 
essentially  these  problems  and  is  presently  the 
most  mature  systems  to  produce  recombinant 
proteins  from  transgenic  organisms.  Now 
experiments  validate  egg  white  as  a  source  of 
foreign proteins including recombinant vaccines. 
1, 
31 
Blood replacement 
The current production system for blood products 
is  donated  human  blood,  and  this  is  limiting 
because  of  disease  concerns,  lack  of  qualified 
donors,  and  regulatory  issues.  Genetically 
engineered animals, such as cattle carrying human 
antibody genes which are able to produce human 
polyclonal  antibodies,  have  the  potential  to 
provide a steady supply of polyclonal antibodies 
for  treatment  of  various  infectious  and  medical 
conditions like organ transplant rejection, cancer, 
and  autoimmune  diseases  and  other  diseases. 
32 
There are currently at least 33 different drugs in 
clinical testing including  several in pivotal trials 
that contain variable regions from transgenic mice 
encoded by human sequences. Also there are 17 
therapeutic MAbs approved by the USFDA which 
are in different phases of drug development. 
33 
Functional human haemoglobin has been produced 
in  transgenic  swine.  The  transgenic  protein 
purified from the  porcine blood  showed oxygen-
binding  characteristics  similar  to  natural  human 
haemoglobin  but  only  a  small  proportion  of 
porcine red blood cells contained human form of 
haemoglobin. 
4 
 
Xenotransplantation  of  porcine  organs  to  human 
patients 
Today  more  than  250,000  people  are  alive  only 
because  of  the  successful  transplantation  of  an 
appropriate  human  organ  (allotransplantation). 
However,  progress  in  organ  transplantation 
technology  has  led  to  an  acute  shortage  of 
appropriate  organs,  and  cadaveric  or  live  organ 
donation does not meet the demand. To close the 
growing gap between demand and availability of 
appropriate human organs, porcine xenografts from 
domesticated  pigs  are  considered  to  be  the  best 
alternative.
4 
Essential  prerequisites  for  a  successful 
xenotransplantation are: 
4, 34 
1. Prevention of transmission of zoonoses 
2. Compatibility of the donor organs in anatomy 
and physiology  
3. Overcoming the immunological rejection of the 
transplanted organ.  
The immunological hurdles are: 
(a)  Hyperacute  rejection  response  (HAR)  occurs 
within seconds or minutes. 
(b) Acute vascular rejection occurs within days. 
(c)  Cellular  rejection  occurs  within  weeks  after 
transplantation.  
(d) Chronic rejection is a complex immunological 
process  resulting  in  the  rejection  of  the 
transplanted organ after several years. 
 
Due  to demand and unavailability  of  appropriate 
organs,  xenotransplantation  is  considered  as  the 
solution of choice. The pig seems to be the optimal 
donor animal because their organs have a similar 
size  as  human  organs,  porcine  anatomy  and 
physiology is same and maintenance is possible at 
high hygienic standards at relatively low costs.
 34, 35 
Two  main  strategies  have  been  successfully 
explored  for  long-term  suppression  of  HAR,  the 
knockout of α-gal epitopes which are the antigenic 
structures on the surface of the porcine cells that 
cause HAR  and synthesis  of  human complement 
regulatory proteins in transgenic pigs. 
31, 34, 36 
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Problems with drugs from transgenic animals: 
Erythropoietin  could  not  be  expressed  in  the 
mammary gland of transgenic cattle. The recovery 
rates of Factor VIII protein were low. 
34 Another 
concern  is  leakage  of  a  target  protein  into  the 
circulation by way of the mammary epithelial cells 
and as measured by increased plasma levels of the 
protein  designed  to  be  expressed  only  in  the 
animal’s milk. 
9 There is also a risk of transmission 
of infection from animal to man. 
31 There are some 
unique concerns such as premature lactational shut 
down  observed  in  some  animals  expressing 
recombinant proteins in their mammary gland. 
37  
While  there  are  problems  associated  with 
transgenic animals, the benefit derived from them 
is far superior and with the increase in technology 
this could be solved.  
 
Drugs  from  Transgenic  Animals  in  Clinical 
Trials 
The approval of  ATryn (rATIII) by USFDA has 
opened  gates  for  other  drugs  from  transgenic 
animals. 
29 Recombinant C1 inhibitor produced in 
the milk of transgenic rabbits has completed phase 
III trials and is expected to receive registration. 
4, 31 
A topical antibiotic against Streptococcus mutans, 
for prevention and treatment of dental caries, has 
completed  phase  III  trials. 
34  Vaccine  used  in 
Alzheimers  disease  has  restored  neurological 
performance in the mice, and is currently in phase 
II  human clinical  trials. 
6α-Glucosidase  from  the 
rabbit is in clinical trial phase II/III for Pompe’s 
disease.  
31, 34  Products such as α-anti-trypsinused 
for cystic fibrosis, α-AT deficiency and tPA used 
for  coronary  clots  are  currently  in  phase  II/III 
clinical trials and are expected to be on the market 
within the next few years.
 34 
Ethics in Transgenic Animals 
Genetic  modification  of  micro-organisms  and 
plants has least concern with regards to ethics but 
when it comes to genetic modification of animals 
and  particularly  humans,  more  objections  are 
registered.  There  remains  concern  that  with 
advances  in  transgenic  animal  technologies  the 
number of animals used for research may actually 
increase  rather  than  reduced  because  of  a  wider 
range of diseases and conditions. 
38 
Ethical concern with oncomouse is that it usually 
suffers  in  order  to  collect  relevant  information, 
which  contradict  the  principles  of  animal 
rights.
6Adenopolyposis  coli  knock-out  mutant 
mice  are  clinically  normal  until  the  intestinal 
polyps develop, after which  mice become anemic 
and  lose  weight.  Each  newly  created  transgenic 
strain has  the potential to cause  poor  health and 
suffering in the animals hence measures need to be 
undertaken to minimize animal suffering. 
39 
Other  ethical  concerns  are  breaching  species 
barriers and animal life should not be regarded as a 
chemical product subject to genetic alteration and 
patentable  for  economic  benefit.  Also  genetic 
engineering of animals interferes with the integrity 
or telos of the animal. Telos is defined as the set of 
needs  and  interests  which  are  genetically  based, 
environmentally expressed, and which collectively 
constitute  or  define  the  form  of  life  or  way  of 
living  exhibited  by  that  animal,  and  whose 
fulfillment or thwarting matter to that animal. 
37 
In  India  attitude  towards  animals  is  tinged  with 
religious and ethical colour which makes religious 
sentiments and  public  awareness necessary to be 
taken  in  consideration.
40  The  3R  (Reduction, 
Refinement,  Replacement)  aim  to  minimize  pain 
experienced  by  the  animals  used  in 
experiments.
29Inspite of the problems listed above, 
transgenic animals may represent a “refinement” in 
comparison to some other traditional experimental 
models of disease where animals bear a heavy load 
of suffering. A genotype is an excellent model of 
disease  for  selected  body  functions  at  the 
molecular or cellular level while the corresponding 
phenotype is completely healthy. Thus it becomes 
necessary  to  consider  the  moral  implications  of 
producing such a species as well as measures of 
reducing animal suffering. 
39  
 
Patents on Transgenic animals 
Patenting  of  animal  models  is  the  need  of  hour, 
because it is an indispensable tool for screening of 
novel  molecule  to  various  diseases.  A  human 
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pathological condition in animals is most important 
to  determine  the  therapeutic  efficacy  of  novel 
molecule. They allow facilitation of the screening 
process to  eliminate inactive moieties and  assess 
the  pharmacologist  to  identify  the  therapeutic 
potential and characterize the toxicological profile 
of novel chemical or biological entities. 
6 
The  two  major  aspects  in  granting  patents  to 
animal  model  are  morality  and  reproducibility. 
6 
Other  concerns  like  restrictive  licensing  of  the 
patents  can  hinder  transfer  of  knowledge. 
41 
Preclinical  animal  models  are  important  in  drug 
discovery,  because  they  lay  the  fundamental  for 
human trials. Patents remain one of the important 
ways of recovery of the investments made by the 
Pharmaceutical companies in research. The Indian 
Patent Law section  3i and  3 j states  that all the 
surgical processes and animals are not patentable, 
hence animal models are not patentable in India. If 
the  suitable  amendments  are  made  then  animal 
models  can  be  patentable  in  India  and  it  would 
open novel vistas in the research arena in India. 
6 
 
Regulation in Transgenic Animals 
Pharmaceutical  research  on  animals  in  India 
depends  on  Department  of  Biotechnology, 
National  Institute  of  Immunology  and 
Environment Protection Act.  An Animal Welfare 
Board  is  constituted,  with  a  Committee  for  the 
Control and Supervision of Experiments Animals 
(CPCSEA) which is in charge of legal and ethical 
aspects or animal research. General Guidelines on 
caring  for  animals  in  research  are  in  accordance 
with  the  International  Committee  for  Laboratory 
Animal  Science  (ICLAS)  Guidelines.  However 
there  is no specific  law or guidelines for cloned 
and transgenic animals. In 2000, Indian Council of 
Medical  Research  Report  promotes  transgenic 
animal research as long as it would pursue a higher 
scientific goal. 
40, 42 
With  changes  in  the  overall  process  of  drug 
discovery, US patents of animal models encourage 
scientists  in  America  and  Europe  to  produce 
animal  models  which  are  very  close  to  human 
disease  and  hence  contribute  significantly  to  the 
process of drug discovery. 
6 The Indian regulatory 
authorities need to be prepared for such challenges 
of  ethics,  regulation  and  patents  in  transgenic 
animals. 
 
Future prospects 
Xenogenic cells,  in particular  from the pig, hold 
great  promise  with  regard  to  successful  cell 
therapy  for  human  patients.  Porcine  islet  cells 
transplanted to diabetic patients has shown to be 
partially functional over a period of time. Porcine 
fetal neural cells have been transplanted into the 
brain  of  patients  suffering  from  Parkinson’s 
disease,  Huntington’s  disease,  stroke  and  focal 
epilepsy.  The  advantages  of  porcine  neural  cells 
over  their  human  counterparts  are  the  abundant 
availability. 
34The pig could be a useful model for 
studying  defects  of  growth-hormone  releasing 
hormone, which are implicated in conditions such 
as  Turner  syndrome,  hypochrondroplasia,  and 
intrauterine growth retardation.
4 
Eggs  provide  other  non-invasive  harvesting 
medium.  Significant  quantities  of  two  human 
proteins,  interferon  beta-1a  and  a  humanized 
monoclonal  antibody  (miR24)  were  expressed  in 
the whites of eggs laid by transgenic hens. miR24 
is being developed for malignant melanoma. 
3 
There are transgenic animals for the development 
of unique biological materials like polymers based 
on  spider  silks  that  may  be  useful  as  suture  or 
plastic  materials  in  facial  and  orthopedic 
restorative surgery. 
43,37 It is impractical to obtain 
sufficient quantities of plasma butylcholinesterase 
(BChE)  to  treat  humans  exposed  to 
organophosphorus  agents  in  agriculture  and 
chemical  warfare,  the  production of  recombinant 
BChE    in  milk  of  transgenic  animals  is  under 
investigation. 
44  It  is  proven  that  the  amount  of 
human  antithrombin  III  obtained  per  year  from 
transgenic goats is equivalent to this resulting from 
90,000 human blood samplings. 
1 Thus transgenic 
animals have the capacity of mass production and 
an  effective  alternative  to  various  human 
byproducts.  Improvements  in  transgenic 
technology  include  inducible  gene  expression, 
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artificial  chromosomes  and  advancement  in 
nuclear transfer. 
34, 45, 36 
Emerging transgenic technologies:
 4, 31, 45 
  Lentiviral transfection of oocytes and zygotes,  
  Chimera generation via injection of pluripotent 
cells into blastocysts 
  Culture  of  spermatogonia  and  transplantation 
into recipient males  
  Ribonucleic acid interference  
Researchers  are  using  transgenic  animals  to 
develop  therapies  for  a  wide  range  of  diseases 
discussed above and other diseases like Anaemia, 
Emphysema,  Haemophilia,  Malaria  and 
Rheumatoid arthritis.
 3 
 
CONCLUSION  
 
Major  prerequisites  for  success  and  safety  of 
transgenic animals will be a continuous refinement 
of reproductive biotechnologies.  In coming years 
genetically modified animals will play a significant 
role in the field of biomedicine especially in drug 
development,  animal  disease  models, 
xenotransplantation,  antibody  production,  gene 
pharming and blood replacement. 
4 The regulatory 
aspects  and  ethics  should  be  given  due 
consideration while using transgenic animals.  
From research, pigs and transgenic animals derived 
products like milk, eggs seems to be promising in 
developments of therapeutic strategies. Drugs from 
transgenic animals can minimize the attrition rate 
in clinical  trials  by  increasing  the  quality  of  the 
target  and  compound  combinations  making  the 
transition  from  discovery  into  development. 
Transgenic technology can impact at many points 
in  the  discovery  process,  including  target 
identification and target validation. It also provides 
models  designed to  alert  researchers early  to the 
potential  problems  with  drug  metabolism  and 
toxicity which will help in providing better models 
for human diseases. 
2  
Transgenic in general is a rapidly advancing field, 
and within 20 years of its inception it has produced 
the  first  USFDA  approved  drug  for  transgenic 
animals. Thus the use of transgenic animals has the 
capacity to overcome the current and future needs 
in medicine and is now a necessity rather than a 
matter of choice.  
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